A phase 1/2 open-label, multicenter, first-in-human study of the safety, tolerability, pharmacokinetics, and antitumor activity of BH-30643 in adult subjects with locally advanced or metastatic NSCLC harboring EGFR and/or HER2 mutations (SOLARA).

Authors: Xiuning Le, Alexander I. Spira, Melissa Lynne Johnson, Misako Nagasaka, Alexander Philipovskiy, Jyoti D. Patel, Sarah W. Gordon, Jonathan W. Riess, Lyudmila Bazhenova, Sonam Puri, Hidehito Horinouchi, Hiroki Izumi, Molly SC Li, Tom John, Sagun Parakh, Armin Graber, Geoff Oxnard, J. Jean Cui, Pingkuan Zhang, James Chih-Hsin Yang

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps8663

Source: Full article

---

Abstract

TPS8663